Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
DocMorris raises forecast after 260% rally and improves operating result
The DocMorris share rose by around 260% over twelve months, driven by a markedly improved operating performance. At its capital markets day the company raised its revenue target to about 15% growth, supported by a strong Rx business (over 90% growth in prescription drugs in October) and improved margins. Adjusted EBITDA is expected to be at worst -10m CHF; a small positive was already achieved in the third quarter, and a free-cash-flow break-even is expected for 2027. Investors should note the strong rally and the earlier 200m CHF capital increase. » More on deraktionaer.de
DocMorris raises outlook after strong sales and prescription growth
DocMorris increased sales in the third quarter by 21% to CHF 343m and reached CHF 971m in the first nine months (+14%). The prescription drug business grew in Q3 by 78% to CHF 108m, active customers rose by 1.5m to 13.1m. For 2026 the company now expects sales growth of 12–15% (in local currency) and lowers the expected EBITDA loss to below CHF 10m. The share price jumped about 8% and hit a 52-week high. » More on deraktionaer.de
Apothekerkammer seizes €110,000 from DocMorris following court rulings
The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands against DocMorris for over €110,000 after the company was said to have breached final German judgments on advertising and discounts. German pharmacists had previously applied for administrative fines and achieved their enforcement in the Netherlands. DocMorris called the measure an enforcement of administrative fines, intends to appeal, and sees no impact on its operations or financial stability. » More on heise.de
Pharmacy chamber seizes €110,000 from DocMorris after breach of German judgments
The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands for €110,000 after DocMorris was said to have violated final German judgments on advertising and discounts. DocMorris described the action as enforcement of administrative fines, announced it would appeal, and stressed that it has no impact on operations or financial stability. The case is part of the years-long dispute between the online provider based in the Netherlands and German brick-and-mortar pharmacies over competitive conditions and cross-border trade. » More on finanzen.net
DocMorris in the Netherlands seized over unpaid fines
A court in Limburg ruled the seizure of accounts belonging to mail-order pharmacy DocMorris lawful after the Apothekerkammer Nordrhein applied for enforcement over unpaid, final administrative fines from Germany. The fines stem from prohibited price advertising, for which Stuttgart imposed several penalties (including €50,000, €60,000 and €100,000); the chamber says unpaid sums run into the millions. DocMorris can appeal within four weeks; the company did not comment on the proceedings. DocMorris is based in Heerlen and generated about €327.2m in revenue on the German market in Q1 2026 (+11.1%). » More on t-online.de
Historical dividends Dividends
All dividend metrics All metricsIn 2016, DocMorris has already paid €0.46 in dividends. The last payout was in June 2016.
Financials
In the last quarter, DocMorris had revenue of €649.14m and net profit of -€57.53m
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 649.14m | - |
| Gross profit | 59.51m | - |
| Net profit | -57.53m | - |
| EBITDA | -21.69m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.01bn |
Number of shares | 50.49m |
52-week high/low | €21.19 - €4.25 |
| Dividends | No |
Beta | 1.86 |
P/E ratio | -11.72 |
PEG ratio | -0.12 |
P/B ratio | 2.53 |
P/S ratio | 0.79 |
Company profile
Zur Rose Group AG operates an e-commerce pharmacy and a wholesale business for medical and pharmaceutical products under the Zur Rose and DocMorris brands in Germany, Switzerland, and rest of Europe. It offers consumer health, beauty, and personal care products. The company also provides medicines management services. It operates stationary pharmacy shops. The company sells its products directly to physicians, online mail-order pharmacies, and private individuals. The company was formerly known as Zur Rose AG and changed its name to Zur Rose Group AG in May 2015. Zur Rose Group AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
| Name | DocMorris |
| CEO | Walter Hess |
| Headquarters | Frauenfeld,
th Switzerland |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 06/07/2017 |
| Employees | 1,454 |
Ticker symbols
| Exchange | Symbol |
|---|---|
SIX | ROSE.SW |
Düsseldorf | ZRE.DU |
Frankfurt | ZRE.F |
London | 0RRB.L |
München | ZRE.MU |
Pnk | ZRSEF |
London Stock Exchange | 0RRB.L |
Nse | IITL.NS |
Australian Securities Exchange Ltd | SRX.AX |
Bse | NILA.BO |
Toronto Stock Exchange | EVGN.V |